The CATT (Comparison of Age-Related Macular Degeneration Treatments Trials) compared ranibizumab vs. bevacizumab for wet AMD. Which conclusion best summarizes the 2-year CATT findings?
- A Ranibizumab was significantly superior to bevacizumab in visual acuity gain at 2 years
- B Bevacizumab was significantly superior to ranibizumab in visual acuity gain with fewer systemic adverse events
- C Both drugs had equivalent visual acuity outcomes; bevacizumab had higher rates of serious systemic adverse events ✓
- D Monthly dosing was equivalent to as-needed dosing for both drugs at 2 years
Correct answer: C. Both drugs had equivalent visual acuity outcomes; bevacizumab had higher rates of serious systemic adverse events
Explanation
The CATT trial (2012) demonstrated that ranibizumab and bevacizumab produced equivalent visual acuity outcomes at 2 years for neovascular AMD. However, bevacizumab was associated with a higher rate of serious systemic adverse events (particularly gastrointestinal events), though the difference was not definitively attributed to the drug. Monthly dosing was superior to as-needed dosing for both agents. Option D is incorrect as monthly dosing maintained a small advantage over PRN dosing.
Reference: Khurana Comprehensive Ophthalmology, 7th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.